Hinge Health, Inc. (HNGE) Delivers Strong Q4 Results and Optimistic 2026 Guidance, Truist Reaffirms Buy Rating

Hinge Health, Inc. (NYSE:HNGE) ranks among the most shorted stocks to buy according to analysts. On February 11, following the company’s fourth-quarter 2025 results, Truist Securities reaffirmed its Buy rating on Hinge Health, Inc. (NYSE:HNGE) and set a price target of $63 on the company’s shares. Analyst Jailendra Singh retained an upbeat assessment after a post-quarterly discussion with Hinge Health’s management to evaluate its financial results and future potential. The exact details of the firm’s discussions with the management weren’t made public.

The company generated earnings per share of $0.49, 250% higher than the expected $0.14, along with revenues of $171 million, a 46% year-over-year increase. Truist cited “multiple upside drivers to an already strong 2026 guidance” in its evaluation of Hinge Health’s position, implying optimism regarding the company’s forward-looking expectations.

Hinge Health, Inc. (NYSE:HNGE) is a musculoskeletal digital clinic that offers personalized physical therapy and pain management programs through a combination of wearable sensors, app-based coaching, and licensed clinical care.

While we acknowledge the potential of HNGE as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the

READ NEXT: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds.

Disclosure: None. Follow Insider Monkey on Google News.